Lift Biosciences Ltd. has been awarded a grant of over £1 million (US$1.3 million) from Innovate UK that will fund a collaboration between Lift and researchers at the University of Cambridge.

Astrazeneca plc has added a novel target for heart failure to its discovery portfolio through its collaboration with Benevolentai Ltd.

A collaboration between Plaquetec Ltd. and a lab at the Babraham Institute has demonstrated the druggability of a pro-inflammatory protein discovered by Plaquetec.

Centogene NV and Evotec SE have announced the discovery of a new small molecule with potential to treat patients with type 2 and type 3 Gaucher disease, or neuronopathic Gaucher disease.

Fogpharma Inc. and Artbio Inc. have established a collaboration to co-develop a new class of α-radioligand therapeutics to maximize efficacy for patients with multiple types of cancer.

Neosphere Biotechnologies GmbH has entered into a collaboration with Kymera Therapeutics Inc. that seeks to unlock undrugged or poorly drugged disease-causing protein targets that can be addressed by targeted protein degradation.

Lantern Pharma Inc. has entered into a strategic artificial intelligence (AI)-driven collaboration with Oregon Therapeutics SAS to optimize the development of Oregon’s first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate XCE-853 in novel and targeted cancer indications.

Cerevance Inc. has announced the achievement of the first milestone in its research collaboration with Merck & Co.

Repertoire Immune Medicines Inc. has entered a multiyear strategic collaboration with Bristol Myers Squibb Co. (BMS) to develop tolerizing vaccines for up to three autoimmune diseases.

Peptidream Inc. and Novartis Pharma AG have expanded their peptide-drug conjugate discovery collaboration announced in 2019, adding additional peptide radioligand therapies and other programs.